Rachel M Layman

15PUBLICATIONS
123CO-AUTHORS
Cancer cell biologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 04, 2026
Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience.

|Mar 09, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano

|Jan 12, 2026
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H Barcenas

|Dec 17, 2025
ER degradation for ER+/HER2- advanced or metastatic breast cancer: a phase 1 trial.

Erika Hamilton, Rachel M Layman, David Cosgrove

|Jul 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Robert Wesolowski, Hope S Rugo, Jennifer M Specht

|May 13, 2025
Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers.

Mohd Mughees, Moises Tacam, Alex W Tan

Pageof 3

Frequent Collaborators

4 joint publications

Erika Hamilton

3 joint publications

Debu Tripathy

3 joint publications

Hope S Rugo

2 joint publications

Bora Lim